Hilton Capital Management LLC Increases Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Hilton Capital Management LLC lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 17.4% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,658 shares of the medical research company’s stock after purchasing an additional 1,135 shares during the period. Hilton Capital Management LLC’s holdings in Charles River Laboratories International were worth $1,508,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. O Shaughnessy Asset Management LLC purchased a new stake in shares of Charles River Laboratories International in the first quarter worth $415,000. UniSuper Management Pty Ltd lifted its position in Charles River Laboratories International by 452.1% in the first quarter. UniSuper Management Pty Ltd now owns 4,003 shares of the medical research company’s stock worth $1,085,000 after buying an additional 3,278 shares during the last quarter. Bessemer Group Inc. boosted its position in shares of Charles River Laboratories International by 456.6% during the first quarter. Bessemer Group Inc. now owns 8,649 shares of the medical research company’s stock valued at $2,343,000 after buying an additional 7,095 shares during the period. Natixis purchased a new stake in Charles River Laboratories International in the first quarter worth $1,058,000. Finally, CreativeOne Wealth LLC bought a new stake in Charles River Laboratories International during the 1st quarter valued at about $201,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Robert W. Baird lowered their price target on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, September 20th. TD Cowen boosted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. Barclays reduced their price target on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a report on Monday. Finally, The Goldman Sachs Group cut their price objective on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $214.38.

Charles River Laboratories International Trading Up 1.0 %

CRL opened at $187.90 on Thursday. Charles River Laboratories International, Inc. has a 1-year low of $176.48 and a 1-year high of $275.00. The firm has a market capitalization of $9.61 billion, a price-to-earnings ratio of 23.52, a price-to-earnings-growth ratio of 4.84 and a beta of 1.38. The company’s 50 day simple moving average is $195.05 and its two-hundred day simple moving average is $206.43. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same period in the previous year, the firm earned $2.72 EPS. Charles River Laboratories International’s revenue was down 1.6% on a year-over-year basis. Analysts expect that Charles River Laboratories International, Inc. will post 10.19 EPS for the current fiscal year.

Charles River Laboratories International announced that its board has authorized a share repurchase program on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to buy up to 9.6% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).